VIENNA — Aflibercept 0.4 mg intravitreal injection in preterm and low birthweight infants with acute-phase retinopathy of prematurity was effective and well tolerated over 5 years of follow-up in a study presented at the Euretina congress.
Based on the original FIREFLEYE study, FIREFLEYE next was the first prospective controlled phase 3b study evaluating the long-term efficacy and safety of Eylea (aflibercept 0.4 mg; Regeneron, Bayer) vs. laser photocoagulation.
“We followed all treated infants for up to 5 years and had a very good retention rate, with 98 out of 113 patients at the end of this